De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

被引:43
|
作者
Nitz, Ulrike [1 ,2 ]
Gluz, Oleg [1 ,2 ,3 ]
Graeser, Monika [1 ,2 ,4 ]
Christgen, Matthias [6 ]
Kuemmel, Sherko [1 ,7 ,8 ]
Grischke, Eva-Maria [9 ]
Braun, Michael [10 ]
Augustin, Doris [11 ]
Potenberg, Jochem [12 ]
Krauss, Katja [13 ]
Schumacher, Claudia [14 ]
Forstbauer, Helmut [15 ]
Reimer, Toralf [16 ,17 ]
Stefek, Andrea [18 ]
Fischer, Hans Holger [19 ]
Pelz, Enrico [20 ]
Zu Eulenburg, Christine [1 ,5 ]
Kates, Ronald [1 ]
Wuerstlein, Rachel [1 ,21 ,22 ]
Kreipe, Hans Heinrich [6 ]
Harbeck, Nadia [1 ,21 ,22 ]
机构
[1] West German Study Grp, Monchengladbach, Germany
[2] Ev Hosp Bethesda, Breast Ctr Niederrhein, Monchengladbach, Germany
[3] Univ Clin Cologne, Cologne, Germany
[4] Univ Med Ctr Hamburg, Dept Gynecol, Hamburg, Germany
[5] Univ Med Ctr Hamburg, Dept Med Biometry & Epidemiol, Hamburg, Germany
[6] Med Sch Hannover, Inst Pathol, Hannover, Germany
[7] Kliniken Essen Mitte, Breast Unit, Essen, Germany
[8] Charite Univ Med Berlin, Dept Gynecol, Breast Ctr, Berlin, Germany
[9] Univ Clin Tuebingen, Womens Clin, Tubingen, Germany
[10] Rotkreuz Clin Munich, Breast Ctr, Munich, Germany
[11] Breast Ctr Ostbayem, Deggendorf, Germany
[12] Ev Waldkrankenhaus Berlin, Berlin, Germany
[13] Univ Clin Aachen, Womens Clin, Aachen, Germany
[14] St Elizabeth Hosp, Breast Ctr, Cologne, Germany
[15] Oncol Practice Network Troisdorf, Troisdorf, Germany
[16] Univ Hosp Gynecol, Rostock, Germany
[17] Policlin Rostock, Rostock, Germany
[18] Evangel Hosp Johanniter, Breast Ctr, Stendal, Germany
[19] Evangel Hosp Gelsenkirchen, Breast Ctr, Gelsenkirchen, Germany
[20] Inst Pathol, Viersen, Germany
[21] Ludwig Maximilians Univ Munchen, Breast Ctr, Dept Gynecol & Obstet, Univ Hosp, D-81377 Munich, Germany
[22] Ludwig Maximilians Univ Munchen, Comprehens Canc Ctr Munich, Univ Hosp, D-81377 Munich, Germany
关键词
PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY; ASSOCIATION; LAPATINIB; EFFICACY; SUBTYPE; SAFETY;
D O I
10.1016/S1470-2045(22)00159-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR- trial and address the effect of pathological complete response, early therapy response, and molecular subtype. Methods WSG-ASAPT-HER2+/ HR-, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m (2) weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease =30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment. Findings Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59,9 months (IQR 53,4-61,4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84- 100) and 87% (78- 93) for invasive disease-free survival (hazard ratio [HR] 0,32, 95% CI 0,07-1,49; p=0,15); 98% (95% CI 84-100) and 89% (79-94) for relapse-free survival (HR 0,41, 95% CI 0,09-1,91; p=0,25); 100% (95% CI not estimable) and 95% (88-98) for locoregional relapse-free survival (HR 0,41, 95% CI 0,05-3,75; p=0,43); 98% (95% CI 84-100) and 92% (83-96) for distant disease-free survival (HR 0,35, 95% CI 0 ,04-3,12; p= 0,36), and 98% (95% CI 84-100) and 94% (86-97) for overall survival (HR 0 ,41, 95% CI 0,05-3,63; p=0 ,43). Pathological complete response was associated with improved invasive disease-free survival (HR 0,14, 95% CI 0,03-0,64; p=0,011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group). Interpretation The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.
引用
收藏
页码:625 / 635
页数:11
相关论文
共 50 条
  • [31] Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
    Cortes, Javier
    Dieras, Veronique
    Ro, Jungsil
    Barriere, Jerome
    Bachelot, Thomas
    Hurvitz, Sara
    Le Rhun, Emilie
    Espie, Marc
    Kim, Sung-Bae
    Schneeweiss, Andreas
    Sohn, Joo Hyuk
    Nabholtz, Jean-Marc
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Taguchi, Julie
    Piacentini, Federico
    Ciruelos, Eva
    Bono, Petri
    Ould-Kaci, Mahmoud
    Roux, Flavien
    Joensuu, Heikki
    LANCET ONCOLOGY, 2015, 16 (16) : 1700 - 1710
  • [32] Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Swain, S. M.
    Ewer, M. S.
    Viale, G.
    Delaloge, S.
    Ferrero, J-M
    Verrill, M.
    Colomer, R.
    Vieira, C.
    Werner, T. L.
    Douthwaite, H.
    Bradley, D.
    Waldron-Lynch, M.
    Kiermaier, A.
    Eng-Wong, J.
    Dang, C.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 646 - 653
  • [33] Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
    Hurvitz, Sara A.
    Andre, Fabrice
    Jiang, Zefei
    Shao, Zhimin
    Mano, Max S.
    Neciosup, Silvia P.
    Tseng, Ling-Min
    Zhang, Qingyuan
    Shen, Kunwei
    Liu, Donggeng
    Dreosti, Lydia M.
    Burris, Howard A.
    Toi, Masakazu
    Buyse, Marc E.
    Cabaribere, David
    Lindsay, Mary-Ann
    Rao, Shantha
    Pacaud, Lida Bubuteishvili
    Taran, Tetiana
    Slamon, Dennis
    LANCET ONCOLOGY, 2015, 16 (07) : 816 - 829
  • [34] Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
    Ismael, Gustavo
    Hegg, Roberto
    Muehlbauer, Susanne
    Heinzmann, Dominik
    Lum, Bert
    Kim, Sung-Bae
    Pienkowski, Tadeusz
    Lichinitser, Mikhail
    Semiglazov, Vladimir
    Melichar, Bohuslav
    Jackisch, Christian
    LANCET ONCOLOGY, 2012, 13 (09) : 869 - 878
  • [35] Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
    Park, Yeon Hee
    Kim, Tae-Yong
    Kim, Gun Min
    Kang, Seok Yun
    Park, In Hae
    Kim, Jee Hyun
    Lee, Kyoung Eun
    Ahn, Hee Kyung
    Lee, Moon Hee
    Kim, Hee-Jun
    Kim, Han Jo
    Lee, Jong In
    Koh, Su-Jin
    Kim, Ji-Yeon
    Lee, Kyung-Hun
    Sohn, Joohyuk
    Kim, Sung-Bae
    Ahn, Jin-Seok
    Im, Young-Hyuck
    Jung, Kyung Hae
    Im, Seock-Ah
    LANCET ONCOLOGY, 2019, 20 (12) : 1750 - 1759
  • [36] Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer
    Julia Foldi
    Sarah Mougalian
    Andrea Silber
    Donald Lannin
    Brigid Killelea
    Anees Chagpar
    Nina Horowitz
    Courtney Frederick
    Lawrence Rispoli
    Trisha Burrello
    Maysa Abu-Khalaf
    Kert Sabbath
    Tara Sanft
    Debra S. Brandt
    Erin W. Hofstatter
    Christos Hatzis
    Michael P. DiGiovanna
    Lajos Pusztai
    Breast Cancer Research and Treatment, 2018, 169 : 333 - 340
  • [37] Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
    Perez-Garcia, Jose M.
    Llombart-Cussac, Antonio
    Cortes, Maria G.
    Curigliano, Giuseppe
    Lopez-Miranda, Elena
    Alonso, Jose L.
    Bermejo, Begona
    Calvo, Lourdes
    Caranana, Vicente
    de la Cruz Sanchez, Susana
    Vazquez, Raul M.
    Prat, Aleix
    Borrego, Manuel R.
    Sampayo-Cordero, Miguel
    Segui-Palmer, Miguel A.
    Soberino, Jesus
    Malfettone, Andrea
    Schmid, Peter
    Cortes, Javier
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 382 - 394
  • [38] Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)
    Pellegrino, Benedetta
    Tommasi, Chiara
    Serra, Olga
    Gori, Stefania
    Cretella, Elisabetta
    Ambroggi, Massimo
    Frassoldati, Antonio
    Bisagni, Giancarlo
    Casarini, Chiara
    Bria, Emilio
    Carbognin, Luisa
    Fiorio, Elena
    Mura, Antonella
    Zamagni, Claudio
    Gianni, Lorenzo
    Zambelli, Alberto
    Montemurro, Filippo
    Tognetto, Michele
    Todeschini, Renata
    Missale, Gabriele
    Campanini, Nicoletta
    Silini, Enrico Maria
    Maglietta, Giuseppe
    Musolino, Antonino
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [39] Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2L trial
    Gluz, O.
    Kuemmel, S.
    Nitz, U.
    Braun, M.
    Luedtke-Heckenkamp, K.
    von Schumann, R.
    Darsow, M.
    Forstbauer, H.
    Potenberg, J.
    Uleer, C.
    Grischke, E. M.
    Aktas, B.
    Schumacher, C.
    zu Eulenburg, C.
    Kates, R.
    Jozwiak, K.
    Graeser, M.
    Wuerstlein, R.
    Baehner, R.
    Christgen, M.
    Kreipe, H. H.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2023, 34 (06) : 531 - 542
  • [40] Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
    Futamura, Manabu
    Ishihara, Kazuhiro
    Nagao, Yasuko
    Ogiso, Atsuko
    Niwa, Yoshimi
    Nakada, Takumi
    Kawaguchi, Yoshihiro
    Ikawa, Ai
    Kumazawa, Iwao
    Mori, Ryutaro
    Kitazawa, Mai
    Hosono, Yoshiki
    Kuno, Masashi
    Kawajiri, Mana
    Nakakami, Akira
    Takeuchi, Makoto
    Morikawa, Akemi
    Tokumaru, Yoshihisa
    Katagiri, Yasuo
    Asano, Yoshimasa
    Mushika, Yoshinori
    Shimokawa, Toshio
    Matsuhasih, Nobuhisa
    BREAST CANCER, 2023, 30 (02) : 293 - 301